Blockchain Registration Transaction Record

Clene Advances Novel ALS Treatment CNM-Au8® Toward FDA Approval

Clene Inc. advances CNM-Au8® oral treatment for ALS toward FDA accelerated approval. Novel mitochondrial therapy shows promise for neurodegenerative diseases with Phase 3 trials planned.

This development matters because ALS (Lou Gehrig's disease) is a devastating neurodegenerative condition with extremely limited treatment options that typically leads to rapid progression and death within 3-5 years of diagnosis. Current FDA-approved treatments offer modest benefits at best, leaving patients and families desperate for new therapeutic approaches. Clene's novel mechanism targeting mitochondrial dysfunction represents a fundamentally different approach that could potentially slow or halt disease progression. If successful, this treatment could significantly improve quality of life and survival for ALS patients while establishing a new paradigm for treating other neurodegenerative diseases like Parkinson's and multiple sclerosis. For investors, it represents an opportunity to support groundbreaking medical innovation while potentially benefiting from the substantial financial upside that successful neurodegenerative disease treatments typically generate.